Cullinan Therapeutics (CGEM) EPS (Weighted Average and Diluted): 2021-2023
Historic EPS (Weighted Average and Diluted) for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$28.97.
- Cullinan Therapeutics' EPS (Weighted Average and Diluted) fell 4894.83% to -$28.97 in Q4 2023 from the same period last year, while for Dec 2023 it was -$32.12, marking a year-over-year decrease of 1449.58%. This contributed to the annual value of -$27.78 for FY2024, which is 13.51% up from last year.
- Per Cullinan Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$28.97 for Q4 2023, which was down 3,083.52% from -$0.91 recorded in Q3 2023.
- Cullinan Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $3.77 for Q2 2022, and its period low was -$28.97 during Q4 2023.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.58 (2022), whereas its average is -$2.81.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 37,800.00% in 2022, then plummeted by 4,894.83% in 2023.
- Over the past 3 years, Cullinan Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.76 in 2021, then increased by 23.68% to -$0.58 in 2022, then slumped by 4,894.83% to -$28.97 in 2023.
- Its last three reported values are -$28.97 in Q4 2023, -$0.91 for Q3 2023, and -$0.82 during Q2 2023.